{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:56:16Z","timestamp":1780631776315,"version":"3.54.1"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Infect Immun"],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Peru-15 is a live attenuated oral vaccine derived from a\n            <jats:italic>Vibrio cholerae<\/jats:italic>\n            O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 \u00d7 10\n            <jats:sup>8<\/jats:sup>\n            CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 10\n            <jats:sup>5<\/jats:sup>\n            CFU of virulent\n            <jats:italic>V. cholerae<\/jats:italic>\n            O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (\u22653,000 g of diarrheal stool) (\n            <jats:italic>P<\/jats:italic>\n            = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool\n            <jats:italic>V. cholerae<\/jats:italic>\n            excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.\n          <\/jats:p>","DOI":"10.1128\/iai.70.4.1965-1970.2002","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T09:59:40Z","timestamp":1027763980000},"page":"1965-1970","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":86,"title":["Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine"],"prefix":"10.1128","volume":"70","author":[{"given":"Mitchell B.","family":"Cohen","sequence":"first","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"Giannella","sequence":"additional","affiliation":[{"name":"Digestive Diseases, University of Cincinnati and VA Medical Center, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Bean","sequence":"additional","affiliation":[{"name":"Center for Epidemiology and Biostatistics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Walter Reed Army Institute of Research, Washington, D.C."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Parker","sequence":"additional","affiliation":[{"name":"Gamble Program for Clinical Studies, Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hoeper","sequence":"additional","affiliation":[{"name":"Gamble Program for Clinical Studies, Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wowk","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Division of Pediatric Gastroenterology, Hepatology and Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sims K.","family":"Kochi","sequence":"additional","affiliation":[{"name":"AVANT Immunotherapeutics, Inc., Needham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Schiff","sequence":"additional","affiliation":[{"name":"Gamble Program for Clinical Studies, Children's Hospital Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Killeen","sequence":"additional","affiliation":[{"name":"AVANT Immunotherapeutics, Inc., Needham, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","first-page":"277","volume":"38","year":"1968","unstructured":"Benenson, A. S., A. Saad, and W. H. Mosley. 1968. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull. W. H. O.38:277-285.","journal-title":"Bull. W. H. O."},{"key":"e_1_3_2_3_2","first-page":"389","volume":"47","year":"1998","unstructured":"Centers for Disease Control and Prevention. 1998. Cholera outbreak among Rwandan refugees-Democratic Republic of Congo, April 1997. Morb. Mortal. Wkly. Rep.47:389-391.","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.4.770"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/145.4.465"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114050"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Graves P. J. Deeks V. Demicheli M. Pratt and T. Jefferson. 2001. Vaccines for preventing cholera. Cochrane Rev. In The Cochrane Library. Oxford United Kingdom. [Online.] www.cochranelibrary.com\n.","DOI":"10.1002\/14651858.CD000974"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.4.1126"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.21.2.174-179.1985"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113201"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/142.3.328"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00006-2"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/514025"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.6.2107-2111.1997"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.5.1968-1972.1998"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)04486-3"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.12.6341-6345.1999"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.6.1518"}],"container-title":["Infection and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.70.4.1965-1970.2002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/IAI.70.4.1965-1970.2002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:43:53Z","timestamp":1646448233000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/IAI.70.4.1965-1970.2002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["10.1128\/IAI.70.4.1965-1970.2002"],"URL":"https:\/\/doi.org\/10.1128\/iai.70.4.1965-1970.2002","relation":{},"ISSN":["0019-9567","1098-5522"],"issn-type":[{"value":"0019-9567","type":"print"},{"value":"1098-5522","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"2001-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2002-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}